240 Leigh Farm Road, Suite 245
Durham, NC 27707
August 6, 2018
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jeff Gabor
Re: Dova Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed July 27, 2018
File No. 333-226403
Acceleration Request
Requested Date: August 8, 2018
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-226403) (the “Registration Statement”) to become effective on August 8, 2018, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”).
Once the Registration Statement has been declared effective, please orally confirm that event with Darren DeStefano of Cooley LLP, counsel to the Registrant, at (703) 456-8034, or in his absence, either of Mark Ballantyne at (703) 456-8084 or Donald Shum at (212) 479-6529.
[Signature page follows]
| Very truly yours, | |
|
| |
| Dova Pharmaceuticals, Inc. | |
|
| |
| By: | /s/ Mark Hahn |
|
| Mark Hahn |
|
| Chief Financial Officer |
cc: Alex Sapir, Dova Pharmaceuticals, Inc.
Marc Banjak, Dova Pharmaceuticals, Inc
Darren DeStefano, Cooley LLP